ALLEGAN (WWJ) – Perrigo Co. (Nasdaq: PRGO) announced that it has received tentative approval from the United States Food & Drug Administration for its abbreviated new drug application for repaglinide tablets, the generic equivalent to Prandin Tablets.
Prandin tablets (repaglinide tablets), are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of approximately $250 million, as measured by Symphony Health Solutions.
“This approval shows the talent and expertise of our R&D and regulatory affairs departments,” said Perrigo president and CEO Joseph C. Papa. “This is another example of Perrigo’s commitment to bring new products to market and deliver on its mission to provide quality, affordable healthcare to consumers.”
From its beginnings as a packager of generic home remedies in 1887, Allegan-based Perrigo has grown into a global developer, manufacturer and distributor of over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The company’s primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia.
More at www.perrigo.com.